Current oncology reports

What We Know About Weight-Loss Drugs Acting on GLP-1 Receptors and Their Link to Obesity-Related Cancers

Updated

Abstract

Obesity is linked to at least 13 types of cancer.

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may lead to significant weight loss.
  • GLP-1RAs are associated with improvements in metabolic and inflammatory processes that could influence cancer development.
  • There is emerging evidence from various study types, including preclinical and randomized trials, connecting GLP-1RAs to obesity-related cancer incidence and outcomes.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free